Clinical trial
A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment
NCT01050322 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment
- Lead sponsor
- Latin American Cooperative Oncology Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- September 30, 2011
- Enrollment
- 142 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.
brms1, patient with a maximum of one chemotherapy, patient with progression after taxanes, performance status zero to two for beginning the study